Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
6.27
+0.07 (1.13%)
At close: Mar 10, 2026
-8.20%
Market Cap 6.44B
Revenue (ttm) 578.61M
Net Income (ttm) 83.77M
Shares Out 1.03B
EPS (ttm) 0.08
PE Ratio 79.25
Forward PE n/a
Dividend 0.02 (0.32%)
Ex-Dividend Date Jul 4, 2025
Volume 12,884,157
Average Volume 22,285,535
Open 6.23
Previous Close 6.20
Day's Range 6.21 - 6.30
52-Week Range 5.98 - 8.74
Beta 0.31
RSI 36.26
Earnings Date Apr 23, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen... [Read more]

Sector Healthcare
Founded 1994
Employees 889
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.